{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T21:36:04Z","timestamp":1769981764796,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:00:00Z","timestamp":1526342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA023074"],"award-info":[{"award-number":["P30CA023074"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00432-018-2662-0","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T07:00:14Z","timestamp":1526367614000},"page":"1317-1327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Characterization of carfilzomib-resistant non-small cell lung cancer cell lines"],"prefix":"10.1007","volume":"144","author":[{"given":"Neale T.","family":"Hanke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliot","family":"Imler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn T.","family":"Marron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce E.","family":"Seligmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda L.","family":"Garland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0670-5381","authenticated-orcid":false,"given":"Amanda F.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,15]]},"reference":[{"key":"2662_CR1","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1021\/mp300044b","volume":"9","author":"L Ao","year":"2012","unstructured":"Ao L et al (2012) Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib. Mol Pharm 9:2197\u20132205. \n                    https:\/\/doi.org\/10.1021\/mp300044b","journal-title":"Mol Pharm"},{"key":"2662_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13046-014-0111-8","volume":"33","author":"AF Baker","year":"2014","unstructured":"Baker AF, Hanke NT, Sands BJ, Carbajal L, Anderl JL, Garland LL (2014) Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models. J Exp Clin Can Res CR 33:111. \n                    https:\/\/doi.org\/10.1186\/s13046-014-0111-8","journal-title":"J Exp Clin Can Res CR"},{"key":"2662_CR3","first-page":"2807","volume":"9","author":"Z Bielcikova","year":"2017","unstructured":"Bielcikova Z, Jakabova A, Pinkas M, Zemanova M, Kolostova K, Bobek V (2017) Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics? Am J Transl Res 9:2807\u20132823","journal-title":"Am J Transl Res"},{"key":"2662_CR4","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/sj.onc.1210028","volume":"26","author":"D Chauhan","year":"2007","unstructured":"Chauhan D et al (2007) A novel Bcl-2\/Bcl-X(L)\/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma Oncogene 26:2374\u20132380. \n                    https:\/\/doi.org\/10.1038\/sj.onc.1210028","journal-title":"Oncogene"},{"key":"2662_CR5","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1021\/cr9000226","volume":"109","author":"PD Eckford","year":"2009","unstructured":"Eckford PD, Sharom FJ (2009) ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 109:2989\u20133011. \n                    https:\/\/doi.org\/10.1021\/cr9000226","journal-title":"Chem Rev"},{"key":"2662_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/leu.2015.289","volume":"30","author":"MA Frassanito","year":"2016","unstructured":"Frassanito MA et al (2016) Halting pro-survival autophagy by TGFbeta inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients Leukemia 30:640\u2013648. \n                    https:\/\/doi.org\/10.1038\/leu.2015.289","journal-title":"Leukemia"},{"key":"2662_CR7","doi-asserted-by":"publisher","first-page":"e20254","DOI":"10.1371\/journal.pone.0020254","volume":"6","author":"C Gareau","year":"2011","unstructured":"Gareau C, Fournier MJ, Filion C, Coudert L, Martel D, Labelle Y, Mazroui R (2011) p21(WAF1\/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis. PLoS One 6:e20254. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0020254","journal-title":"PLoS One"},{"key":"2662_CR8","first-page":"490","volume":"81","author":"TM Grogan","year":"1993","unstructured":"Grogan TM et al (1993) P-glycoprotein expression in human plasma cell myeloma: correlation with. Prior Chemother Blood 81:490\u2013495","journal-title":"Prior Chemother Blood"},{"key":"2662_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00432-015-2047-6","volume":"142","author":"NT Hanke","year":"2016","unstructured":"Hanke NT, Garland LL, Baker AF (2016) Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol 142:549\u2013560. \n                    https:\/\/doi.org\/10.1007\/s00432-015-2047-6","journal-title":"J Cancer Res Clin Oncol"},{"key":"2662_CR10","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071\u20133076","journal-title":"Cancer Res"},{"key":"2662_CR11","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.2217\/fon.14.30","volume":"10","author":"Z Huang","year":"2014","unstructured":"Huang Z, Wu Y, Zhou X, Xu J, Zhu W, Shu Y, Liu P (2014) Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials. Future Oncol 10:1795\u20131807. \n                    https:\/\/doi.org\/10.2217\/fon.14.30","journal-title":"Future Oncol"},{"key":"2662_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/CE.S13838","volume":"6","author":"S Jain","year":"2011","unstructured":"Jain S, Diefenbach C, Zain J, O\u2019Connor OA (2011) Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Core Evid 6:43\u201357. \n                    https:\/\/doi.org\/10.2147\/CE.S13838","journal-title":"Core Evid"},{"key":"2662_CR13","first-page":"187","volume":"15","author":"N Komatsu","year":"2006","unstructured":"Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW, Koeffler HP (2006) SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 15:187\u2013191","journal-title":"Oncol Rep"},{"key":"2662_CR14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq. 2 Genome Biol 15:550. \n                    https:\/\/doi.org\/10.1186\/s13059-014-0550-8","journal-title":"2 Genome Biol"},{"key":"2662_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1124\/jpet.108.138131","volume":"326","author":"S Lu","year":"2008","unstructured":"Lu S et al (2008) Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma\/leukemia line. J Pharmacol Exp Ther 326:423\u2013431. \n                    https:\/\/doi.org\/10.1124\/jpet.108.138131","journal-title":"J Pharmacol Exp Ther"},{"key":"2662_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-3-319-06752-0_5","volume":"3","author":"AK Mitra","year":"2014","unstructured":"Mitra AK, Stessman H, Shaughnessy J, Van Ness B (2014) Profiling bortezomib resistance in multiple myeloma: implications in personalized pharmacotherapy Resist Target Anti-C 3:117\u2013147 \n                    https:\/\/doi.org\/10.1007\/978-3-319-06752-0_5","journal-title":"Resist Target Anti-C"},{"key":"2662_CR17","doi-asserted-by":"publisher","first-page":"e581","DOI":"10.1038\/bcj.2017.56","volume":"7","author":"AK Mitra","year":"2017","unstructured":"Mitra AK et al (2017) A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. Blood Cancer J 7:e581. \n                    https:\/\/doi.org\/10.1038\/bcj.2017.56","journal-title":"Blood Cancer J"},{"key":"2662_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O\u2019Connor","year":"2005","unstructured":"O\u2019Connor OA et al. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma J Clin Oncol 23:676\u2013684 \n                    https:\/\/doi.org\/10.1200\/JCO.2005.02.050","journal-title":"J Clin Oncol"},{"key":"2662_CR19","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","volume":"112","author":"R Oerlemans","year":"2008","unstructured":"Oerlemans R et al (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112:2489\u20132499. \n                    https:\/\/doi.org\/10.1182\/blood-2007-08-104950","journal-title":"Blood"},{"key":"2662_CR20","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00280-013-2267-x","volume":"72","author":"KP Papadopoulos","year":"2013","unstructured":"Papadopoulos KP et al (2013) A phase I\/II study of carfilzomib 2\u201310-min infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol 72:861\u2013868. \n                    https:\/\/doi.org\/10.1007\/s00280-013-2267-x\n                    \n                   [doi]","journal-title":"Cancer Chemother Pharmacol"},{"key":"2662_CR21","doi-asserted-by":"publisher","first-page":"E8379-E8386","DOI":"10.1073\/pnas.1608461113","volume":"113","author":"SM Park","year":"2016","unstructured":"Park SM et al (2016) Molecular profiling of single circulating tumor cells from lung cancer patients. Proc Natl Acad Sci USA 113:E8379-E8386. \n                    https:\/\/doi.org\/10.1073\/pnas.1608461113","journal-title":"Proc Natl Acad Sci USA"},{"key":"2662_CR22","doi-asserted-by":"publisher","first-page":"14814","DOI":"10.18632\/oncotarget.4530","volume":"6","author":"I Riz","year":"2015","unstructured":"Riz I, Hawley TS, Hawley RG (2015) KLF4-SQSTM1\/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models Oncotarget 6:14814\u201314831. \n                    https:\/\/doi.org\/10.18632\/oncotarget.4530","journal-title":"Oncotarget"},{"key":"2662_CR23","doi-asserted-by":"publisher","first-page":"66360","DOI":"10.18632\/oncotarget.11960","volume":"7","author":"I Riz","year":"2016","unstructured":"Riz I, Hawley TS, Marsal JW, Hawley RG (2016) Noncanonical SQSTM1\/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic translational reprogramming Oncotarget 7:66360\u201366385. \n                    https:\/\/doi.org\/10.18632\/oncotarget.11960","journal-title":"Oncotarget"},{"key":"2662_CR24","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/leu.2009.8","volume":"23","author":"T Ruckrich","year":"2009","unstructured":"Ruckrich T et al (2009) Characterization of the ubiquitin-proteasome system in bortezomib-adapted. Cells Leukemia 23:1098\u20131105. \n                    https:\/\/doi.org\/10.1038\/leu.2009.8","journal-title":"Cells Leukemia"},{"key":"2662_CR25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.bbrc.2007.07.049","volume":"361","author":"H Rumpold","year":"2007","unstructured":"Rumpold H, Salvador C, Wolf AM, Tilg H, Gastl G, Wolf D (2007) Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors Biochem Biophys Res Commun 361:549\u2013554 \n                    https:\/\/doi.org\/10.1016\/j.bbrc.2007.07.049","journal-title":"Biochem Biophys Res Commun"},{"key":"2662_CR26","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1182\/blood-2012-04-422121","volume":"120","author":"SA Rushworth","year":"2012","unstructured":"Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ (2012) The high Nrf2 expression in human acute myeloid leukemia is driven by NF-kappaB and underlies its chemo. Resist Blood 120:5188\u20135198. \n                    https:\/\/doi.org\/10.1182\/blood-2012-04-422121","journal-title":"Resist Blood"},{"key":"2662_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1600-0609.2007.00902.x","volume":"79","author":"R Schmidmaier","year":"2007","unstructured":"Schmidmaier R, Baumann P, Bumeder I, Meinhardt G, Straka C, Emmerich B (2007) First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma European. J Haematol 79:240\u2013243. \n                    https:\/\/doi.org\/10.1111\/j.1600-0609.2007.00902.x","journal-title":"J Haematol"},{"key":"2662_CR28","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel DS et al (2012) A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Blood 120:2817\u20132825","journal-title":"Blood"},{"key":"2662_CR29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1124\/jpet.111.187542","volume":"341","author":"SE Verbrugge","year":"2012","unstructured":"Verbrugge SE et al (2012) Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein\/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther 341:174\u2013182. \n                    https:\/\/doi.org\/10.1124\/jpet.111.187542","journal-title":"J Pharmacol Exp Ther"},{"key":"2662_CR30","doi-asserted-by":"publisher","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","volume":"119","author":"R Vij","year":"2012","unstructured":"Vij R et al (2012) An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma Blood 119:5661\u20135670. \n                    https:\/\/doi.org\/10.1182\/blood-2012-03-414359","journal-title":"Blood"},{"key":"2662_CR31","doi-asserted-by":"publisher","first-page":"e0178302","DOI":"10.1371\/journal.pone.0178302","volume":"12","author":"JM Yeakley","year":"2017","unstructured":"Yeakley JM, Shepard PJ, Goyena DE, VanSteenhouse HC, McComb JD, Seligmann BE (2017) A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS One 12:e0178302. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0178302","journal-title":"PLoS One"},{"key":"2662_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1476-4598-9-110","volume":"9","author":"L Zhang","year":"2010","unstructured":"Zhang L, Littlejohn JE, Cui Y, Cao X, Peddaboina C, Smythe WR (2010) Characterization of bortezomib-adapted I-45 mesothelioma. Cells Mol Cancer 9:110. \n                    https:\/\/doi.org\/10.1186\/1476-4598-9-110","journal-title":"Cells Mol Cancer"},{"key":"2662_CR33","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2147\/OTT.S130742","volume":"10","author":"Z Zheng","year":"2017","unstructured":"Zheng Z, Liu T, Zheng J, Hu J (2017) Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction network. Onco Targets Ther 10:1327\u20131334. \n                    https:\/\/doi.org\/10.2147\/OTT.S130742","journal-title":"Onco Targets Ther"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-018-2662-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2662-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2662-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T19:57:57Z","timestamp":1557863877000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-018-2662-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["2662"],"URL":"https:\/\/doi.org\/10.1007\/s00432-018-2662-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]},"assertion":[{"value":"20 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Compliance with ethical standards"}},{"value":"Authors EI, MTM, and BES are employees of BioSpyder Technologies, Inc., the company that developed and now sells the TempO-Seq kits. The other authors have no conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No human participants were used in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}